I joined the Oxford Vaccine Group Department of Paediatrics as a senior statistician in 2017 after receiving more than 4 years of training as a Research Fellow (Clinical Trial Statistician) at the Imperial Clinical Trial Unit.
My experiences in trials cover a broad range of therapeutic areas, including cancer, surgery, nutrition and vaccination and ranging from early phase to late phase. My research interest is mainly in developing efficient trial designs and practical implementation of such designs in clinical trials, for example, model based adaptive designs in early phase dose-finding trials evaluating safety and efficacy. I am also interested in applying biomarkers in late phase trial design and benefit and risk assessment.
I am actively involved in postgraduate teaching. I designed a 4-hour training course ‘Introduction to Statistics’ for MSc in Cancer Biology students and was co-leader of the ‘Introduction to Statistics R practical module’ for MSc in Epidemiology students while working at the Imperial College London. I have also been involved in tutoring in a few other courses, such as Bayesian Statistics and Advanced Topics in Biostatistics. I have supervised two MSc students for their summer projects and one NIHR Research Methods Fellow at the Imperial Clinical Trial Unit.
I completed a Preventive Medicine Degree at Peking University in 2005. After that, I was trained in Epidemiology and Biostatistics at Peking University and University of Cambridge and obtained my PhD and MPhil degrees.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
Rollier CS. et al, (2022), Vaccine
Prevention of typhoid by Vi conjugate vaccine and achievable improvements in household WASH: Evidence from a cluster-randomized trial in Dhaka, Bangladesh.
Tadesse BT. et al, (2022), Clin Infect Dis
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Liu X. et al, (2022), J Infect
Prevention of Typhoid Fever by Existing Improvements in Household Water, Sanitation, and Hygiene, and the Use of the Vi Polysaccharide Typhoid Vaccine in Poor Urban Slums: Results from a Cluster-Randomized Trial.
Im J. et al, (2022), Am J Trop Med Hyg, 106, 1149 - 1155